Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chronic graft-vs-host disease.
Bhushan V, Collins RH Jr. Bhushan V, et al. Among authors: collins rh jr. JAMA. 2003 Nov 19;290(19):2599-603. doi: 10.1001/jama.290.19.2599. JAMA. 2003. PMID: 14625337 Review. No abstract available.
In vitro methotrexate as a practical approach to selective allodepletion.
Sathe A, Ortega SB, Mundy DI, Collins RH, Karandikar NJ. Sathe A, et al. Among authors: collins rh. Biol Blood Marrow Transplant. 2007 Jun;13(6):644-54. doi: 10.1016/j.bbmt.2007.01.081. Epub 2007 Mar 23. Biol Blood Marrow Transplant. 2007. PMID: 17531774 Free article.
Long-term outcome of progressive multifocal leukoencephalopathy with recombinant interleukin-2 treatment and an associated increase in the number of HPyV-2-specific T-cells: a case report.
Hoff FW, Rolwes J, Hardeman PA, Perkins M, Major EO, Douek D, Collins RH Jr, Greenberg BM. Hoff FW, et al. Among authors: collins rh jr. Ther Adv Hematol. 2023 Oct 9;14:20406207231201721. doi: 10.1177/20406207231201721. eCollection 2023. Ther Adv Hematol. 2023. PMID: 37822572 Free PMC article.
Use of ferumoxides for stem cell labeling.
Sadek H, Latif S, Collins R, Garry MG, Garry DJ. Sadek H, et al. Regen Med. 2008 Nov;3(6):807-16. doi: 10.2217/17460751.3.6.807. Regen Med. 2008. PMID: 18947305
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Atallah E, Collins R Jr, Kantarjian H, Jabbour E, Wilhelm FE, Azarnia N, Silverman LR; ONTIME study investigators. Garcia-Manero G, et al. Lancet Oncol. 2016 Apr;17(4):496-508. doi: 10.1016/S1470-2045(16)00009-7. Epub 2016 Mar 9. Lancet Oncol. 2016. PMID: 26968357 Clinical Trial.
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
Stein EM, Fathi AT, DiNardo CD, Pollyea DA, Roboz GJ, Collins R, Sekeres MA, Stone RM, Attar EC, Frattini MG, Tosolini A, Xu Q, See WL, MacBeth KJ, de Botton S, Tallman MS, Kantarjian HM. Stein EM, et al. Lancet Haematol. 2020 Apr;7(4):e309-e319. doi: 10.1016/S2352-3026(19)30284-4. Epub 2020 Mar 5. Lancet Haematol. 2020. PMID: 32145771 Clinical Trial.
139 results